-+ 0.00%
-+ 0.00%
-+ 0.00%

ROCKET PHARMACEUTICALS HIGHLIGHTS FDA-ALIGNED PIVOTAL PHASE 2 TRIAL AND UPDATED CLINICAL FINDINGS FOR RP-A501 FOLLOWING DANON DISEASE INVESTOR WEBINAR

Reuters·10/07/2026 13:37:07